In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

@article{Bitner2010InVP,
  title={In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.},
  author={Robert S. Bitner and William H. Bunnelle and Michael W. Decker and Karla U. Drescher and Kathy L. Kohlhaas and Stella Markosyan and Kennan C. Marsh and Arthur L. Nikkel and Kaitlin E. Browman and Rich Radek and David J. Anderson and Jerry Buccafusco and Murali Gopalakrishnan},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2010},
  volume={334 3},
  pages={
          875-86
        }
}
We previously reported that alpha7 nicotinic acetylcholine receptor (nAChR) agonism produces efficacy in preclinical cognition models correlating with activation of cognitive and neuroprotective signaling pathways associated with Alzheimer's disease (AD) pathology. In the present studies, the selective and potent alpha7 nAChR agonist 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy] pyridazin-3-yl)-1H-indole (ABT-107) was evaluated in behavioral assays representing distinct cognitive domains. Studies… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery.

  • Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES